- ISIN
- US75383L1026
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 7, 2024
Highlights
- Market Cap
- $1.96B
- Enterprise Value
- $1.90B
- EPS (TTM)
- -$2.44
- Total Revenue (TTM)
- $20.00M
- Gross Profit (TTM)
- -$265.00K
- EBITDA (TTM)
- -$118.37M
- Year Range
- $13.62 - $44.28
- Target Price
- $49.00
- ROA (TTM)
- -21.56%
- ROE (TTM)
- -22.75%
- Avg. Volume (1M)
- 370K
- Avg. Volume Value (1M)
- $15.22M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
RAPP Performance Chart
Rapport Therapeutics, Inc (RAPP) is up 35.1% since the beginning of the year. At $41 per share, RAPP is trading 7.5% below its 52-week high of $44.
Loading charts...
Compare this symbol against anything
Returns By Period
Rapport Therapeutics, Inc (RAPP) has returned 35.07% so far this year and 189.61% over the past 12 months.
Rapport Therapeutics, Inc
- 1D
- -4.21%
- 1M
- 5.16%
- 6M
- 54.00%
- YTD
- 35.07%
- 1Y
- 189.61%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- 46.71%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
RAPP Monthly Returns History
Based on dividend-adjusted daily data since Jun 7, 2024, RAPP's average daily return is +0.39%, while the average monthly return is +5.31%. At this rate, an investment would double in approximately 1.1 years.
Historically, 54% of months were positive and 46% were negative. The best month was Sep 2025 with a return of +68.5%, while the worst month was Feb 2025 at -38.9%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 4 months.
On a daily basis, RAPP closed higher 51% of trading days. The best single day was Sep 8, 2025 with a return of +119.2%, while the worst single day was Mar 3, 2025 at -28.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -12.29% | 9.09% | 7.79% | 5.88% | 19.23% | 5.49% | -1.66% | 35.07% | |||||
| 2025 | -7.50% | -38.88% | 0.00% | 14.16% | -27.77% | 37.48% | 26.30% | 22.77% | 68.46% | -2.59% | 2.70% | 2.12% | 71.03% |
| 2024 | 29.22% | -2.32% | -4.27% | -5.84% | 19.78% | -6.89% | -22.33% | -1.44% |
Benchmark Metrics
Rapport Therapeutics, Inc has an annualized alpha of 112.48%, beta of 1.35, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since June 07, 2024.
- This stock captured 242.68% of S&P 500 Index gains and 110.33% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 112.48%
- Beta
- 1.35
- R²
- 0.03
- Upside Capture
- 242.68%
- Downside Capture
- 110.33%
Return for Risk
Risk / Return Rank
RAPP ranks 93 for risk / return — above 93% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Rapport Therapeutics, Inc (RAPP) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| RAPP | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.04 | ||
| Sortino ratioReturn per unit of downside risk | +1.77 | ||
| Omega ratioGain probability vs. loss probability | 1.46 | 1.25 | +0.20 |
| Calmar ratioReturn relative to maximum drawdown | 6.47 | 2.00 | +4.47 |
| Martin ratioReturn relative to average drawdown | 16.63 | 8.49 | +8.14 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Rapport Therapeutics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Rapport Therapeutics, Inc was 75.54%, occurring on Mar 3, 2025. Recovery took 130 trading sessions.
The current Rapport Therapeutics, Inc drawdown is 4.21%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-75.54%Mar 2025 | 4mo 17d | 6mo 9d | 10mo 26dOct 2024 - Sep 2025 | 2025 selloff2025 |
-33.73%Aug 2024 | 26d | 2mo 5d | 3mo 1dJul 2024 - Oct 2024 | — |
-28.82%Sep 2025 | 1d | 3mo 13d | 3mo 14dSep 2025 - Dec 2025 | — |
-20.39%Jun 2024 | 1d | 1mo 5d | 1mo 5dJun 2024 - Jul 2024 | — |
-19.91%Feb 2026 | 1mo 14d | 1mo 26d | 3mo 10dDec 2025 - Apr 2026 | — |
Drawdown Indicators
| RAPP | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -75.54% | -56.78% | -18.76% |
Max Drawdown (1Y)Largest decline over 1 year | -28.82% | -9.10% | -19.72% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -4.21% | -1.58% | -2.63% |
Average DrawdownAverage peak-to-trough decline | -27.55% | -10.70% | -16.85% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 11.20% | 2.14% | +9.06% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Rapport Therapeutics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Rapport Therapeutics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for RAPP relative to other companies in the Biotechnology industry. Currently, RAPP has a P/S ratio of 90.3. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for RAPP in comparison with other companies in the Biotechnology industry. Currently, RAPP has a P/B value of 4.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with RAPP
Add Rapport Therapeutics, Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with RAPP